Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Ascentage Pharma Group International banner

Ascentage Pharma Group International
OTC:ASPHF

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
OTC:ASPHF
Watchlist
Price: 8.48 USD
Market Cap: $2.7B
Write Note Create Alert Ask AI

Relative Value

The Relative Value of one ASPHF stock under the Base Case scenario is hidden USD. Compared to the current market price of 8.48 USD, Ascentage Pharma Group International is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ASPHF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

P/S
View Details
P/E
View Details
P/OCF
View Details
P/FCFE
View Details
P/B
View Details
EV/S
View Details
EV/GP
View Details
EV/EBITDA
View Details
EV/EBIT
View Details
EV/OCF
View Details
EV/FCFF
View Details
EV/IC
View Details

Multiples Across Competitors

ASPHF Competitors Multiples
Ascentage Pharma Group International Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Ascentage Pharma Group International
OTC:ASPHF
17B USD 38.8 -13.1 -12.9 -12.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
405.4B USD 6.8 172.1 16.6 23.6
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD 462 374.5 -2 631.9 -2 377 -2 377
US
Amgen Inc
NASDAQ:AMGN
204.5B USD 5.6 26.7 15.2 15.2
US
Gilead Sciences Inc
NASDAQ:GILD
183B USD 6.3 21.6 14.7 14.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.8B USD 10.3 31.3 23.9 25
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.4B USD 5.7 18.3 13.9 15.8
NL
argenx SE
XBRU:ARGX
43.5B EUR 14.3 33.7 57.9 59.5
AU
CSL Ltd
ASX:CSL
70.5B AUD 3.1 16.3 11.2 14
P/S Multiple
Revenue Growth P/S to Growth
CN
Ascentage Pharma Group International
OTC:ASPHF
Average P/S: 3 100 710.8
38.8
24%
1.6
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
10%
0.7
US
Astria Therapeutics Inc
NASDAQ:ATXS
462 374.5
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.6
3%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
6.3
5%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
11%
0.9
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
P/E Multiple
Earnings Growth PEG
CN
Ascentage Pharma Group International
OTC:ASPHF
Average P/E: 45.7
Negative Multiple: -13.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.1
89%
1.9
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 631.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.7
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.6
14%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
17%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
NL
argenx SE
XBRU:ARGX
33.7
42%
0.8
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Ascentage Pharma Group International
OTC:ASPHF
Average EV/EBITDA: 21.9
Negative Multiple: -12.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 377 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.2
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.7
18%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
15%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
23%
0.6
NL
argenx SE
XBRU:ARGX
57.9
810%
0.1
AU
CSL Ltd
ASX:CSL
11.2
8%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Ascentage Pharma Group International
OTC:ASPHF
Average EV/EBIT: 24
Negative Multiple: -12.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 377 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.2
2%
7.6
US
Gilead Sciences Inc
NASDAQ:GILD
14.7
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
21%
0.8
NL
argenx SE
XBRU:ARGX
59.5
N/A N/A
AU
CSL Ltd
ASX:CSL
14
11%
1.3

See Also

Summary
ASPHF intrinsic value, competitors valuation, and company profile.
DCF Valuation
ASPHF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ASPHF stock valuation using valuation multiples.
Wall Street Estimates
ASPHF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ASPHF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 320,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.